Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Available × Familial Hypophosphatemic Rickets × Clear all

Status

Completed 1 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Neoplasms 11 Carcinoma, Non-Small-Cell Lung 8 Recurrence 6 Prostatic Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Neuroblastoma 6 Multiple Myeloma 6 Sarcoma 5 Pancreatic Neoplasms 5 Ovarian Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Leukemia, Myeloid, Acute 4 Glioblastoma 4 Stomach Neoplasms 3 Hematologic Neoplasms 3 Head and Neck Neoplasms 3 Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Small Cell Lung Carcinoma 2 Primary Myelofibrosis 2 Pheochromocytoma 2 Osteosarcoma 2 Non-Muscle Invasive Bladder Neoplasms 2 Neuroectodermal Tumors, Primitive 2 Neoplasm Metastasis 2 Myelodysplastic Syndromes 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03775187 2025-03-05

Expanded Access to Burosumab

Kyowa Kirin Co., Ltd.

Oncogenic osteomalacia, Familial Hypophosphatemic Rickets

Data powered by HemOnc (CC BY 4.0) Colophon ⚡